TUOXIN PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.5 CNY | +2.76% |
|
-10.50% | -37.97% |
| Sales 2022 | 785M 108M 8.64B | Sales 2023 | 836M 115M 9.2B | Capitalization | 6.83B 944M 75.29B |
|---|---|---|---|---|---|
| Net income 2022 | 287M 39.64M 3.16B | Net income 2023 | 243M 33.56M 2.68B | EV / Sales 2022 | 10.9 x |
| Net cash position 2022 | 507M 70.05M 5.59B | Net cash position 2023 | 339M 46.85M 3.74B | EV / Sales 2023 | 7.77 x |
| P/E ratio 2022 |
31.7
x | P/E ratio 2023 |
28
x | Employees | 1,550 |
| Yield 2022 |
0.56% | Yield 2023 |
0.46% | Free-Float | 40.5% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.76% | ||
| 1 week | -10.50% | ||
| Current month | -17.39% | ||
| 1 month | -17.39% | ||
| 3 months | -24.70% | ||
| 6 months | -33.57% | ||
| Current year | -37.97% |
1 week
31.35
33.79
1 month
31.3543.33
Current year
31.3557.45
1 year
31.3589.97
3 years
25.10230.00
5 years
25.10230.00
10 years
25.10230.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Juan Jiao
DFI | Director of Finance/CFO | 58 | 30/11/11 |
Tao Li
CTO | Chief Tech/Sci/R&D Officer | 43 | 30/06/05 |
Xiu Qiang Wang
BRD | Director/Board Member | 54 | 31/07/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Ning Yang
CHM | Chairman | 62 | 31/07/05 |
Lin Xian Sheng
BRD | Director/Board Member | 69 | 31/07/05 |
Yu Ying Cai
BRD | Director/Board Member | 61 | 31/07/05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 33.5 | +2.76% | 3,707,513 |
| 26/04/24 | 32.6 | +0.43% | 3,395,194 |
| 25/04/24 | 32.46 | +1.18% | 3,920,503 |
| 24/04/24 | 32.08 | -1.32% | 4,346,195 |
| 23/04/24 | 32.51 | -13.14% | 7,632,814 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Tuoxin Pharmaceutical Group Co Ltd, formerly Xinxiang Tuoxin Pharmaceutical Co Ltd, is a Chinese company mainly engaged in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates. The Company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series and other series of nucleoside (acid) products, including citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, uridine and other raw materials and pharmaceutical intermediates. Its products are mainly used in the fields of virus, anti-tumor and nervous system drugs. The Company mainly distributes its products in domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -37.97% | 586M | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.41% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B |
- Stock Market
- Equities
- 301089 Stock
